Rotenone-induced parkinsonism in rats is a widely used animal model of parkinsonism for studies of the antiparkinsonism activity of new substances. The guanidine derivatives of adamantane 1-adamantylguanidine hydrochloride (IEM-2151) and 3,5-dimethyl-1-adamantylguanidine hydrochloride (IEM-2163) given p.o. at a dose of 10 mg/kg had signifi cantly greater antiparkinsonism effects than levodopa at a dose of 20 mg/kg and memantine at a dose of 5 mg/kg, as they reduced the proportion of rats with severe oligokinesia 1.5–3 times more effectively than memantine and levodopa and, in contrast to memantine and levodopa, completely eliminated severe catalepsy in rats with rotenone-induced parkinsonism. IEM-2151 was the safest substance, as it prevented lethality among rats throughout the experiment, while memantine and levodopa increased lethality among the animals towards the end of the experiment. Combined p.o. administration of levodopa with IEM-2151 at the low doses of 10 and 5 mg/kg, respectively, produced a maximal synergistic antiparkinsonism effect, which was greater than the effects of each drug alone at twice the dose. The combination of IEM-2151 with levodopa at low therapeutic doses is a potentially effective and safe approach to the treatment of levodopa-refractory parkinsonism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
V. E. Gmiro and S. E. Serdyuk, “Comparative analysis of the NMDA-blocking activity and safety of monocationic and dicationic compounds in animal experiments,” Eksperim. Klin. Farmakol., 63, No. 6, 3–8 (2000).
G. A. Grigor’yan and A. S. Bazyan, “Experimental models of Parkinson’s disease in animals,” Usp. Fiziol. Nauk., 38, No. 4, 80–88 (2007).
I. G. Kapitsa, E. A. Ivanova, A. V. Nepoklonov, et al., “The effects of himantane and amantadine on the development of levodopa-induced dyskinesia on a model of Parkinson’s syndrome in rats,” Eksperim. Klin. Farmakol., 74, No. 7, 9–12 (2011).
O. S. Levin and L. A. Batukaeva, “Effi cacy of memantine in Parkinson’s disease with dementia,” Zh. Nevrol. Psikhiat., 108, No. 12, 16–23 (2008).
F. A. Ahmadi, T. N. Grammatopoulos, A. M. Poczobutt, et al., “Dopamine selectively sensitizes dopaminergic neurons to rotenone-induced apoptosis,” Neurochem. Res., 33, No. 5, 886–901 (2008).
M. Alam, and W. J. Schmidt, “L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats,” Behav. Brain Res., 153, No. 2, 439–446 (2004).
J. R. Cannon, V. Tapias, H. M. Na, et al., “A highly reproducible rotenone model of Parkinson’s disease,” Neurobiol. Dis., 34, No. 2, 279–290 (2009).
W. Danysz, C. G. Parsons, J. Kornhuber, et al., “Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies,” Neurosci. Biobehav. Rev., 21, No. 4, 455–468 (1997).
S. M. Fleming, C. Zhu, P. O. Fernagut, et al., “Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone,” Exp. Neurol., 187, No. 2, 418–429 (2004).
T. Hayakawa, Y. Sugimoto, Z. Chen, et al., “Effects of anti-Parkinsonian drugs on neurobehavioural changes induced by bilateral 6-hydroxydopamine lesions in rats,” Clin. Exp. Pharmacol. Physiol., 26, No. 5–6, 421–425 (1999).
M. T. Herrero, J. Pagonabarraga, and G. Linazasoro, “Neuroprotective role of dopamine agonists: evidence from animal models and clinical studies,” Neurologist, 17, No. 6, Suppl. 1, S54–S66 (2011).
C. Ikonomidou, V. Stefovska, and L. Turski, “Neuronal death enhanced by N-methyl-D-aspartate antagonists,” Proc. Natl. Acad. Sci. USA, 97, No. 2, 12885–12890 (2000).
C. Kobylecki, M. A. Cenci, A. R. Crossman, and P. Ravenscroft, “Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson’s disease,” J. Neurochem., 114, No. 2, 499–511 (2010).
C. H. Lin, J. Y. Huang, C. H. Ching, and J. I. Chuang, “Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats,” J. Pineal Res., 44, No. 2, 205–213 (2008).
G. Losi, M. Lanza, F. Makovec, et al., “Functional in vitro characterization of CR 3394: a novel voltage dependent N-methyl-D-aspartate (NMDA) receptor antagonist,” Neuropharmacology, 50, No. 3, 277–285 (2006).
K. S. Madathil, S. S. Karuppagounder, R. Haobam, et al., “Nitric oxide synthase inhibitors protect against rotenone-induced, oxidative stress mediated parkinsonism in rats,” Neurochem. Int., 62, No. 5, 674–683 (2013).
N. B. Mercuri and G. Bernardi, “The ‘magic’ of L-dopa: why is it the gold standard Parkinson’s disease therapy?” Trends Pharmacol. Sci., 26, No. 7, 341–344 (2005).
N. Nakao, K. Nakai, and T. Itakura, “Metabolic inhibition enhances selective toxicity of L-DOPA toward mesencephalic dopamine neurons in vitro,” Brain Res., 777, No. 1–2, 202–209 (1997).
G. Rammes, W. Danysz, and C. G. Parsons, “Pharmacodynamics of memantine: an update,” Curr. Neuropharmacol., 6, No. 1, 55–78 (2008).
O. Rascol, A. Lozano, M. Stern, and W. Poewe, “Milestones in Parkinson’s disease therapeutics,” Mov. Disord., 26, No. 6, 1072–1082 (2011).
N. I. Rukoyatkina, L. V. Gorbunova, V. E. Gmiro, and N. Y. Lukomskaya, “The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals,” Neurosci. Behav. Physiol., 33, No. 3, 273–278 (2003).
W. J. Schmidt and M. Alam, “Controversies on new animal models of Parkinson’s disease pro and con: the rotenone model of Parkinson’s disease (PD),” J. Neural Transm., 70, Supplement, 273–276 (2006).
S. Swarnkar, S. Singh, R. Mathur, et al., “A study to correlate rotenone induced biochemical changes and cerebral damage in brain areas with neuromuscular coordination in rats,” Toxicology, 272, No. 1–3, 17–22 (2010).
Y. N. Wu and S. W. Johnson, “Dopamine oxidation facilitates rotenone-dependent potentiation of N-methyl-D-aspartate currents in rat substantia nigra dopamine neurons,” Neuroscience, 195, 138–144 (2011).
Y. N. Wu, and S. W. Johnson, “Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of a-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity,” Neurosci. Res., 71, No. 4, 387–395 (2011).
Y. Yang, X. Liu, Y. Long, et al., “Systematic administration of iptakalim, an ATP-sensitive potassium channel opener, prevents rotenoneinduced motor and neurochemical alterations in rats,” J. Neurosci. Res., 80, No. 3, 442–449 (2005).
Y. Yang, X. Liu, Y. Long, et al., “Activation of mitochondrial ATPsensitive potassium channels improves rotenone-related motor and neurochemical alterations in rats,” Int. J. Neuropsychopharmacol., 9, No. 1, 51–61 (2006).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Rossiiskii Fiziologicheskii Zhurnal imeni I. M. Sechenova, Vol. 103, No. 7, pp. 768–777, July, 2017.
Rights and permissions
About this article
Cite this article
Gmiro, V.E., Serdyuk, S.E. & Veselkina, O.S. Comparison of the Antiparkinson Activity of Levodopa, Memantine, and Guanidine-Containing Analogs of Amantadine and Memantine (IEM-2151 and IEM-2163) in Rats with Rotenone-Induced Parkinsonism. Neurosci Behav Physi 49, 502–507 (2019). https://doi.org/10.1007/s11055-019-00762-8
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-019-00762-8